UNSPSC 51284606: Panipenem

This classification denotes a beta-lactam antibiotic with the molecular formula C15H21N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W9769W09JF, chemically known as 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-3-((1-(1-iminoethyl)-3-pyrrolidinyl)thio)-7-oxo-, (5r-(3(s*),5-alpha,6-alpha(r*)))- but generally known as panipenem, which bears US NIH Compound Identifier 72015.

UNSPSC 51284606 Panipenem is a Commodity code for a specific pharmaceutical active ingredient; however, the recent state and local opportunities tagged under this code do not reflect procurement of panipenem itself. Instead, the tagged solicitations are for other pharmaceutical products — antibiotic tablets (Doxycycline Hyclate, Ciprofloxacin Hydrochloride) and naloxone with drug deactivation systems — that fall outside panipenem's scope. State and local governments appear to use this code inconsistently or as a proxy for broader pharmaceutical supply categories. The issuing bodies are health and human services agencies: the Illinois Department of Public Health and Seminole County, Florida, both acquiring medications and medical supplies through cooperative purchasing vehicles and competitive bidding.

The recent activity spans Illinois and Florida. The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026 (Solicitation 26482DPHPREPDB53392) for antibiotic tablets totaling $2,999,999.11 over a three-year term including renewals; this was a completed award, not an open opportunity. Seminole County, Florida released an IFB (Solicitation IFB60459723LAS) on June 30, 2026 with a July 26, 2023 response deadline for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries required and all shipping costs to be included in the bid price. The mismatch between the code's nominal scope and the actual products being procured suggests that panipenem as a standalone line item sees minimal recent state and local activity, or that jurisdictions are applying this code as a catch-all for pharmaceutical acquisitions rather than for panipenem specifically.